JP7429988B2 - セリンベータ－ラクタマーゼのインヒビターとしてのジアザビシクロオクタノン - Google Patents

セリンベータ－ラクタマーゼのインヒビターとしてのジアザビシクロオクタノン Download PDF

Info

Publication number
JP7429988B2
JP7429988B2 JP2021506575A JP2021506575A JP7429988B2 JP 7429988 B2 JP7429988 B2 JP 7429988B2 JP 2021506575 A JP2021506575 A JP 2021506575A JP 2021506575 A JP2021506575 A JP 2021506575A JP 7429988 B2 JP7429988 B2 JP 7429988B2
Authority
JP
Japan
Prior art keywords
alkyl
unsubstituted
substituted
halogen
thiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021506575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534095A5 (https=
JP2021534095A (ja
Inventor
レリス，シモン
トーマス デイビス，デイビッド
Original Assignee
アンタビオ エスアーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290093.6A external-priority patent/EP3608318A1/en
Priority claimed from EP18213635.8A external-priority patent/EP3670512A1/en
Application filed by アンタビオ エスアーエス filed Critical アンタビオ エスアーエス
Publication of JP2021534095A publication Critical patent/JP2021534095A/ja
Publication of JP2021534095A5 publication Critical patent/JP2021534095A5/ja
Application granted granted Critical
Publication of JP7429988B2 publication Critical patent/JP7429988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021506575A 2018-08-09 2019-08-08 セリンベータ－ラクタマーゼのインヒビターとしてのジアザビシクロオクタノン Active JP7429988B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18290093.6 2018-08-09
EP18290093.6A EP3608318A1 (en) 2018-08-09 2018-08-09 Diaazabicyclooctanone derivatives as antibacterials
EP18213635.8A EP3670512A1 (en) 2018-12-18 2018-12-18 Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP18213635.8 2018-12-18
PCT/EP2019/071370 WO2020030761A1 (en) 2018-08-09 2019-08-08 Diazabicyclooctanones as inhibitors of serine beta-lactamases

Publications (3)

Publication Number Publication Date
JP2021534095A JP2021534095A (ja) 2021-12-09
JP2021534095A5 JP2021534095A5 (https=) 2022-08-18
JP7429988B2 true JP7429988B2 (ja) 2024-02-09

Family

ID=67667824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506575A Active JP7429988B2 (ja) 2018-08-09 2019-08-08 セリンベータ－ラクタマーゼのインヒビターとしてのジアザビシクロオクタノン

Country Status (24)

Country Link
US (1) US12378244B2 (https=)
EP (2) EP4272831A3 (https=)
JP (1) JP7429988B2 (https=)
KR (1) KR102790878B1 (https=)
CN (2) CN111954671B (https=)
AU (1) AU2019318115B2 (https=)
BR (1) BR112021002311A2 (https=)
CA (1) CA3110111A1 (https=)
DK (1) DK3833665T3 (https=)
ES (1) ES2960952T3 (https=)
FI (1) FI3833665T3 (https=)
HR (1) HRP20231228T1 (https=)
HU (1) HUE063324T2 (https=)
IL (1) IL280770B2 (https=)
LT (1) LT3833665T (https=)
MX (1) MX2021001564A (https=)
PL (1) PL3833665T3 (https=)
RS (1) RS64679B1 (https=)
SG (1) SG11202101255UA (https=)
SI (1) SI3833665T1 (https=)
SM (1) SMT202300354T1 (https=)
TW (1) TWI764030B (https=)
WO (1) WO2020030761A1 (https=)
ZA (1) ZA202100906B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN117700415B (zh) * 2024-02-06 2024-04-30 成都四面体药物研究有限公司 含脲双环化合物、其用途、其制备的药物、其联合用药物及其复方制剂
WO2025215253A1 (en) * 2024-04-12 2025-10-16 Antabio Sas Dosing regimen comprising (2r,5r)-2-fluoro-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate and a beta-lactam antibiotic

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510012A (ja) 2008-01-18 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
JP2014525434A (ja) 2011-08-30 2014-09-29 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
JP2015512440A (ja) 2012-04-02 2015-04-27 アストラゼネカ アクチボラグ β−ラクタマーゼ阻害剤としてのヘテロ二環式化合物
JP2016503000A (ja) 2012-12-11 2016-02-01 フェドラ・ファーマシューティカルズ・インコーポレイテッド 新規二環式化合物、ならびに抗菌剤およびβ−ラクタマーゼ阻害剤としてのその使用
CN107501265A (zh) 2017-10-09 2017-12-22 台州职业技术学院 一种7‑氧代‑二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用
WO2019093450A1 (ja) 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
JP2020528412A (ja) 2017-07-21 2020-09-24 アンタビオ エスアーエス 化学的化合物

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012601A1 (en) 1993-11-06 1995-05-11 Taiho Pharmaceutical Co., Ltd. Crystalline penicillin derivative, and its production and use
MXPA01009808A (es) 1999-04-01 2002-04-24 Dsm Nv Aglomerados por cristalizacion.
ATE518540T1 (de) 1999-08-16 2011-08-15 Revaax Pharmaceuticals Llc Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
US20030148324A1 (en) 2001-02-02 2003-08-07 Edouard Bingen Polynucleotides which are of nature B2/D+ A- and which are isolated from E. coli, and biological uses of these polynucleotides and of their polypeptides
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
SE0102058D0 (sv) 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DE10218328A1 (de) 2002-03-05 2003-09-25 Humboldt Uni Zu Berlin Medizin Mittel zur präventiven Therapie nach akutem Schlaganfall
EP1342784A1 (en) 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
CA2493870C (en) 2002-03-13 2010-07-20 Creighton University Device and method for detecting antibiotic inactivating enzymes
FR2842210B1 (fr) 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US6928313B2 (en) 2003-01-27 2005-08-09 Cardiac Pacemakers, Inc. System and method for accessing the coronary sinus to facilitate insertion of pacing leads
EP1715866A2 (en) 2004-02-05 2006-11-02 The General Hospital Corporation Protease inhibitors for treatment of wrinkles
EP1580195A1 (en) 2004-03-26 2005-09-28 Mutabilis SA Compositions of polypeptides specific to pathogenic ExPEC E. coli strains and their use as vaccines and in immunotherapy
ATE476981T1 (de) 2004-12-02 2010-08-15 Venus Remedies Ltd Zusammensetzungen zur bekämpfung von beta- lactamase-vermittelter antibiotischer resistenz mittels beta-lactamase-hemmern für injektionen
EP1669365A1 (en) 2004-12-03 2006-06-14 Mutabilis SA Method for preparing enzymatic substrate analogs as inhibitors of bacterial heptosyl-transferases
EP1861110B1 (en) 2004-12-17 2014-03-26 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
CA2641605A1 (en) 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
CA2641616A1 (en) 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
EP1845087A1 (en) 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
US20100261618A1 (en) 2006-06-19 2010-10-14 Sonia Escaich Identification of genes implicated in the virulence of streptococcus agalactiae
AU2007301607A1 (en) 2006-09-25 2008-04-03 Mutabilis Sa Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
EP1972629A1 (en) 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP2141164A1 (en) 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof
UY32174A (es) 2008-10-14 2010-05-31 Astrazeneca Ab Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
AU2010313228B2 (en) 2009-10-30 2014-05-29 Biogenic Innovations, Llc Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
EP2646451A2 (en) 2010-12-01 2013-10-09 Laboratoire Biodim Heptose derivatives for use in the treatment of bacterial infections
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
KR102143660B1 (ko) 2011-06-17 2020-08-11 화이자 안티-인펙티브스 에이비 트랜스-7-옥소-6-(술포옥시)-1,6-디아자비시클로[3,2,1]옥탄-2-카르복스아미드 및 그의 염을 포함하는 헤테로시클릭 화합물의 제조 방법
US9744160B2 (en) 2011-07-26 2017-08-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
WO2013062995A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating deep partial and full thickness wounds and injuries
WO2013062994A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating full thickness burn injuries
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
KR20150003777A (ko) 2012-03-30 2015-01-09 큐비스트 파마슈티컬즈 인코포레이티드 이속사졸 β-락타마제 억제제
RU2693898C2 (ru) 2012-05-30 2019-07-05 Мейдзи Сейка Фарма Ко., Лтд. НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ
BR112015003592B1 (pt) 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
RU2671485C2 (ru) 2012-09-27 2018-11-01 Мерк Шарп И Доум Корп. Антибиотические композиции тазобактама аргинина
EP2725029A1 (en) 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
RU2676482C2 (ru) 2013-01-14 2018-12-29 Вокхардт Лимитед Композиции и способы лечения бактериальных инфекций
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
WO2014122468A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
ES2495666B1 (es) 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
MX2016005160A (es) 2013-10-22 2016-10-05 Wockhardt Ltd Composiciones farmaceuticas que comprenden agentes antibacterianos.
US9822115B2 (en) 2014-01-21 2017-11-21 Wockhardt Limited Nitrogen containing compounds and their use as antibacterial agents
EP3102578A1 (en) 2014-02-03 2016-12-14 Wockhardt Limited A process for preparation of (2s, 5r)-1,6-diaza-bicyclo [3.2.1]octane-2-carbonitrile-7-oxo-6-(sulfooxy)-mono sodium salt
JP2017506240A (ja) 2014-02-20 2017-03-02 ウォックハート リミテッド 抗菌剤を含む医薬組成物
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
CN106794250A (zh) 2014-03-14 2017-05-31 沃克哈特有限公司 包含抗菌剂的药物组合物
MX373444B (es) 2014-03-24 2020-04-30 Novartis Ag Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas.
US20170027917A1 (en) 2014-04-18 2017-02-02 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
EP3131583A1 (en) 2014-04-18 2017-02-22 The Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
EA033459B1 (ru) 2014-05-29 2019-10-31 Entasis Therapeutics Ltd Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
KR102542392B1 (ko) 2014-11-17 2023-06-09 엔타시스 테라퓨틱스 리미티드 내성 박테리아 감염의 치료를 위한 배합물 치료제
GB2533136A (en) 2014-12-11 2016-06-15 Antabio Sas Compounds
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2016128867A1 (en) 2015-02-12 2016-08-18 Wockhardt Limited Azetidinone containing compounds and their use in treatment of bacterial infections
TW201639853A (zh) 2015-03-31 2016-11-16 木塔比利斯公司 雜環化合物及其於預防或治療細菌感染之用途
BR112017020796A2 (pt) 2015-03-31 2018-06-26 Mutabilis compostos, composição farmacêutica e kit
CN107438614B (zh) 2015-04-03 2020-01-31 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CA2983674A1 (en) 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017002086A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002087A1 (en) 2015-07-02 2017-01-05 Wockhardtlimited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002083A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
CN106467705B (zh) 2015-08-17 2019-02-22 3M创新有限公司 防滑液、防滑件及其制备方法
WO2017037607A1 (en) 2015-09-01 2017-03-09 Wockhardt Limited (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity
CN108463461B (zh) 2015-12-10 2021-11-19 奈加-Rgm制药有限公司 头孢烯化合物、其制备和用途
EP3184529A1 (en) 2015-12-23 2017-06-28 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017156239A1 (en) 2016-03-11 2017-09-14 California Institute Of Technology Compositions and methods for acylating lactams
WO2017203266A1 (en) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
WO2017216765A1 (en) 2016-06-17 2017-12-21 Wockhardt Limited Antibacterial compositions
CN114591223B (zh) 2016-09-16 2025-01-24 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物
EP3300736B1 (en) 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
WO2018129008A1 (en) 2017-01-04 2018-07-12 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections
KR20190115062A (ko) 2017-02-06 2019-10-10 무타빌리스 새로운 헤테로사이클릭 화합물 및 이의 세균 감염 치료 또는 예방 용도
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
NZ758200A (en) 2017-05-08 2025-12-19 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
EP3604315A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3604309A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) * 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510012A (ja) 2008-01-18 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
JP2014525434A (ja) 2011-08-30 2014-09-29 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
JP2015512440A (ja) 2012-04-02 2015-04-27 アストラゼネカ アクチボラグ β−ラクタマーゼ阻害剤としてのヘテロ二環式化合物
JP2016503000A (ja) 2012-12-11 2016-02-01 フェドラ・ファーマシューティカルズ・インコーポレイテッド 新規二環式化合物、ならびに抗菌剤およびβ−ラクタマーゼ阻害剤としてのその使用
JP2020528412A (ja) 2017-07-21 2020-09-24 アンタビオ エスアーエス 化学的化合物
CN107501265A (zh) 2017-10-09 2017-12-22 台州职业技术学院 一种7‑氧代‑二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用
WO2019093450A1 (ja) 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体

Also Published As

Publication number Publication date
ZA202100906B (en) 2023-07-26
DK3833665T3 (da) 2023-10-09
SG11202101255UA (en) 2021-03-30
RS64679B1 (sr) 2023-11-30
CN117384155A (zh) 2024-01-12
LT3833665T (lt) 2023-11-10
AU2019318115A1 (en) 2021-03-11
WO2020030761A1 (en) 2020-02-13
IL280770B2 (en) 2024-05-01
IL280770A (en) 2021-04-29
FI3833665T3 (fi) 2023-10-09
TWI764030B (zh) 2022-05-11
US20240391919A1 (en) 2024-11-28
CA3110111A1 (en) 2020-02-13
AU2019318115B2 (en) 2024-04-18
EP3833665A1 (en) 2021-06-16
EP4272831A3 (en) 2024-02-21
SMT202300354T1 (it) 2023-11-13
EP4272831A2 (en) 2023-11-08
KR102790878B1 (ko) 2025-04-02
PL3833665T3 (pl) 2023-12-27
HRP20231228T1 (hr) 2024-01-19
KR20210055701A (ko) 2021-05-17
EP3833665B1 (en) 2023-07-19
SI3833665T1 (sl) 2023-12-29
HUE063324T2 (hu) 2024-01-28
BR112021002311A2 (pt) 2021-05-04
MX2021001564A (es) 2021-05-12
ES2960952T3 (es) 2024-03-07
JP2021534095A (ja) 2021-12-09
CN111954671B (zh) 2023-09-01
TW202019929A (zh) 2020-06-01
CN111954671A (zh) 2020-11-17
IL280770B1 (en) 2024-01-01
US12378244B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
JP7429988B2 (ja) セリンベータ－ラクタマーゼのインヒビターとしてのジアザビシクロオクタノン
JP2013515070A5 (https=)
US20220315546A1 (en) Chemical compounds
US11905286B2 (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
HK40102805A (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
EA042632B1 (ru) Диазабициклооктаноны в качестве ингибиторов сериновых бета-лактамаз
EP3670512A1 (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
HK40044097B (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
HK40044097A (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3608318A1 (en) Diaazabicyclooctanone derivatives as antibacterials
AU2023305002A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
HK40020428A (en) Chemical compounds
HK40020428B (en) Chemical compounds
EA038487B1 (ru) Производные тиазолов, содержащая их фармацевтическая композиция и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220808

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240123

R150 Certificate of patent or registration of utility model

Ref document number: 7429988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150